Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Cg Oncology Inc (NASDAQ: CGON) was $38.0 for the day, down -0.34% from the previous closing price of $38.13. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 0.74 million shares were traded. CGON stock price reached its highest trading level at $38.735 during the session, while it also had its lowest trading level at $37.435.
Ratios:
Our analysis of CGON’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.15 and its Current Ratio is at 22.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
On May 02, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $41.JP Morgan initiated its Overweight rating on May 02, 2025, with a $41 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 30 ’25 when POST LEONARD E sold 5,000 shares for $40.09 per share. The transaction valued at 200,450 led to the insider holds 0 shares of the business.
Mulay James sold 12,755 shares of CGON for $499,868 on Sep 29 ’25. The Director now owns 0 shares after completing the transaction at $39.19 per share. On Sep 30 ’25, another insider, LEONARD E POST, who serves as the Director of the company, bought 5,000 shares for $39.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 2897408256 and an Enterprise Value of 2237350144. For the stock, the TTM Price-to-Sale (P/S) ratio is 5268.01 while its Price-to-Book (P/B) ratio in mrq is 4.32. Its current Enterprise Value per Revenue stands at 4060.526 whereas that against EBITDA is -14.243.
Stock Price History:
The Beta on a monthly basis for CGON is 1.34, which has changed by 0.094470024 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $40.65, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is 22.31%, while the 200-Day Moving Average is calculated to be 38.29%.
Shares Statistics:
CGON traded an average of 932.47K shares per day over the past three months and 750330 shares per day over the past ten days. A total of 76.23M shares are outstanding, with a floating share count of 45.56M. Insiders hold about 40.24% of the company’s shares, while institutions hold 77.36% stake in the company. Shares short for CGON as of 1757894400 were 11010990 with a Short Ratio of 11.81, compared to 1755216000 on 10328902. Therefore, it implies a Short% of Shares Outstanding of 11010990 and a Short% of Float of 15.290000000000001.
Earnings Estimates
The performance of Cg Oncology Inc (CGON) in the stock market is under the watchful eye of 9.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$2.17, with 9.0 analysts recommending between -$0.9 and -$3.8.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for CGON’s current fiscal year. The highest revenue estimate was $9.5M, while the lowest revenue estimate was $52k, resulting in an average revenue estimate of $1.51M. In the same quarter a year ago, actual revenue was $1.14M
